SOTERA HEALTH COMPANY (SHC) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | (m) | Operating Income (Loss) |
| Revenue | 1.22B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | |
| Selling, general and administration | 257.18M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.22B | (m) | (m) | $257.18M | (m) |
| 2026-03-31 | (m) | $1.19B | (m) | (m) | $257.91M | (m) |
| 2025-12-31 | (m) | $1.16B | (m) | (m) | $252.76M | (m) |
| 2025-09-30 | (m) | $1.15B | (m) | (m) | $257.08M | (m) |
| 2025-06-30 | (m) | $1.12B | (m) | (m) | $255.80M | (m) |
| 2025-03-31 | (m) | $1.11B | (m) | (m) | $247.48M | (m) |
| 2024-12-31 | $297.63M | $1.10B | (m) | (m) | $242.63M | 27.05% |
| 2024-09-30 | $314.50M | $1.12B | (m) | (m) | $241.15M | 28.07% |
| 2024-06-30 | $310.10M | $1.10B | (m) | (m) | $233.25M | 28.24% |
| 2024-03-31 | $296.50M | $1.08B | (m) | (m) | $232.97M | 27.53% |
| 2023-12-31 | $276.69M | $1.05B | (m) | (m) | $236.67M | 26.37% |
| 2023-09-30 | $232.84M | $990.64M | (m) | (m) | $242.26M | 23.50% |
| 2023-06-30 | $219.93M | $976.17M | (m) | (m) | $245.24M | 22.53% |
| 2023-03-31 | $228.22M | $987.52M | (m) | (m) | $248.08M | 23.11% |
| 2022-12-31 | $248.35M | $1.00B | (m) | (m) | $245.71M | 24.74% |
| 2022-09-30 | $254.61M | $993.35M | (m) | (m) | $231.59M | 25.63% |
| 2022-06-30 | $257.08M | $970.81M | (m) | (m) | $218.54M | 26.48% |
| 2022-03-31 | $263.86M | $956.08M | (m) | (m) | $205.24M | 27.60% |
| 2021-12-31 | $256.73M | $931.48M | (m) | (m) | $198.16M | 27.56% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $206.02M | $818.16M | (m) | (m) | $178.53M | 25.18% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $183.60M | $778.33M | (m) | (m) | $147.48M | 23.59% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |